Plain-English translation of NCT07278882 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a mobile app can help children with acute lymphoblastic leukemia (ALL) during their outpatient maintenance therapy — the long-term treatment phase after initial intensive chemotherapy. The app analyzes your child's daily medication records and weekly blood test results, then sends alerts if the medication dosing is on track, needs attention, or needs urgent action. The goal is to see if this technology helps keep children's medication doses in the safe and effective range.
Keeping the right medication dose during long-term leukemia treatment is challenging for families managing care at home. This trial exists to see if a mobile app can make it easier to stay on track, reduce dosing errors, and ultimately improve treatment outcomes.
You likely qualify if…
You likely don't qualify if…
If your child is in the intervention group, you will use a mobile app to log your child's daily medication doses and weekly blood test results. The app will then classify the dosing status as 'On Track,' 'Orange Alert,' or 'Red Alert' to help you monitor progress. If your child is in the control group, you will continue standard care without the app. The trial will track whether the app helps keep medication doses in the target range over time.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Enrollment target
~100 participants
Started
December 2025
Primary completion
November 2027
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yahui Feng
Institute of Hematology & Blood Diseases Hospital, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.